COVID-19 Presentation and Outcomes among Cancer Patients: A Matched Case-Control Study.

COVID-19 cancer matched cohort study mortality prognosis

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
21 Oct 2021
Historique:
received: 14 09 2021
revised: 12 10 2021
accepted: 18 10 2021
entrez: 13 11 2021
pubmed: 14 11 2021
medline: 14 11 2021
Statut: epublish

Résumé

It has been suggested that cancer patients are at higher risk of contracting COVID-19 and at higher risk of developing a severe form of the disease and fatality. This study's objectives were to measure the excess risk of mortality and morbidity of patients with cancer among patients hospitalized for a SARS-CoV-2 infection, and to identify factors associated with the risk of death and morbidity among cancer patients. All first cancer patients hospitalized for COVID-19 in the two main hospitals of the Lyon area were included. These patients were matched based on age, gender, and comorbidities with non-cancer control patients. A total of 108 cancer patients and 193 control patients were included. The severity at admission and the symptoms were similar between the two groups. The risk of early death was higher among cancer patients, while the risk of intubation, number of days with oxygen, length of stay in ICU, and length of hospital stay were reduced. The main factors associated with early death among cancer patients was the severity of COVID-19 and the number of previous chemotherapy lines. The outcomes appear to be driven by the severity of the infection and therapeutic limitations decided at admission.

Identifiants

pubmed: 34771446
pii: cancers13215283
doi: 10.3390/cancers13215283
pmc: PMC8582532
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Crit Rev Oncol Hematol. 2021 Jul;163:103365
pubmed: 34052423
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
Ann Oncol. 2020 Aug;31(8):1065-1074
pubmed: 32442581
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
JAMA Oncol. 2021 Aug 1;7(8):1133-1140
pubmed: 34047765
Lancet Oncol. 2020 Jul;21(7):893-903
pubmed: 32479790
Cancer Discov. 2020 Jul;10(7):935-941
pubmed: 32357994
SN Compr Clin Med. 2020 Oct 23;:1-10
pubmed: 33134842
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Lancet Oncol. 2020 Oct;21(10):1309-1316
pubmed: 32853557
Lancet Oncol. 2021 Jun;22(6):765-778
pubmed: 33930323
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Curr Opin Pulm Med. 1996 Sep;2(5):396-404
pubmed: 9363174
BMJ Health Care Inform. 2021 May;28(1):
pubmed: 33980502
Ann Oncol. 2020 Aug;31(8):1088-1089
pubmed: 32330541
J Infect Dis. 2020 May 11;221(11):1762-1769
pubmed: 32227123
Cancer Cell. 2021 Aug 9;39(8):1091-1098.e2
pubmed: 34214473
Eur J Cancer. 2021 Aug;153:123-132
pubmed: 34153714
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
JNCI Cancer Spectr. 2021 Jan 06;5(1):pkaa090
pubmed: 33604509
J Clin Virol. 2020 Jun;127:104361
pubmed: 32344320
Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2
pubmed: 34133951
BMJ. 2020 Apr 29;369:m1735
pubmed: 32349991

Auteurs

Julien Péron (J)

Medical Oncology Department, Institut de Cancérologie des Hospices Civils de Lyon, 69002 Lyon, France.
Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, CNRS UMR 5558, Université Claude Bernard Lyon 1, 69100 Villeurbanne, France.
Faculté de Médecine et de Maïeutique Lyon-Sud-Charles Mérieux, Université Claude Bernard Lyon 1, 69310 Pierre-Bénite, France.

Tristan Dagonneau (T)

Medical Information Department, Hospices Civils de Lyon, 69002 Lyon, France.

Anne Conrad (A)

Infectious Diseases Department, Croix-Rousse Hospital, 69004 Lyon, France.
Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, University of Lyon, 69007 Lyon, France.

Fanny Pineau (F)

Clinical Research Plateform, Institut de Cancérologie des Hospices Civils de Lyon, 69002 Lyon, France.

Sara Calattini (S)

Clinical Research Plateform, Institut de Cancérologie des Hospices Civils de Lyon, 69002 Lyon, France.

Gilles Freyer (G)

Medical Oncology Department, Institut de Cancérologie des Hospices Civils de Lyon, 69002 Lyon, France.
Faculté de Médecine et de Maïeutique Lyon-Sud-Charles Mérieux, Université Claude Bernard Lyon 1, 69310 Pierre-Bénite, France.

David Perol (D)

Centre Léon Bérard, 69008 Lyon, France.

Christophe Sajous (C)

Medical Oncology Department, Institut de Cancérologie des Hospices Civils de Lyon, 69002 Lyon, France.
Faculté de Médecine et de Maïeutique Lyon-Sud-Charles Mérieux, Université Claude Bernard Lyon 1, 69310 Pierre-Bénite, France.

Maël Heiblig (M)

Faculté de Médecine et de Maïeutique Lyon-Sud-Charles Mérieux, Université Claude Bernard Lyon 1, 69310 Pierre-Bénite, France.
Haematology Department, Institut de Cancérologie des Hospices Civils de Lyon, 69310 Pierre-Bénite, France.

Classifications MeSH